The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
Tycel Phillips, MD, questioned how the regimen of acalabrutinib, bendamustine, and rituximab would compare with taking the drugs separately in mantle cell lymphoma.
The phase 3 MECCA trial represents the largest data set investigating the efficacy of metronomic chemo-endocrine combination therapy in metastatic breast cancer, according to researchers.
Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.
W. Kimryn Rathmell has stepped down as NCI director, opting to hand her resignation to the Biden administration over facing the uncertainties that Trump and…
The FDA has granted priority review to sunvozertinib for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations after progression on chemotherapy.
Combining aerobic and resistance-based physical activity with dexamethasone may improve quality of life and reduce the effects of fatigue.
To join a team for the 2025 SurgOnc Bowl, please complete the following questionnaire. For more information and the rules of engagement, please visit this…
The determination of unbiased cancer risk estimates in hereditary breast and ovarian cancer syndrome (HBOC) poses several challenges. The article by Katona and colleagues is…
Stem cell transplant programs at the Dana-Farber Brigham Cancer Center received outstanding reviews from the CIBMTR.
Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses his key myelodysplastic syndrome (MDS) highlights from this year’s ASH meeting.…
